April.2018-March.2019

Announcement of an additional investigational site opening for the Phase I clinical study for OTS167 (oral administration) in patients with Breast Cancer including Triple-Negative Breast Cancer

Publication of a paper describing the anti-cancer effect of a MELK inhibitor OTS167 on neuroblastoma

Announcement of the Initiation of Phase I Clinical Study of Cancer-Specific Peptide Vaccine S-588210 for Solid Tumor Patients

Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410

Announcement of the Initiation of Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer

The announcement of the additional investigational site opening of Phase I clinical study for OTS167 (oral administration) in patients with Breast Cancer including Triple-Negative Breast Cancer

Announcement of the presentation of interim results for exploratory study of peptide vaccine S-588410 at European Society for Medical Oncology 2018 Congress.

Announcement of research collaboration between OTS’s subsidiary company, SECOM Medical System Co., Ltd., and Yotsuya Medical Cube to accelerate the Cancer Precision Medicine

Publication of a paper on the development of small molecule compounds inhibiting a novel anti-cancer drug target

Announcement of the press release from QST regarding the publication of novel α-emitter radioisotope-labeled therapy for synovial sarcoma